GSA Capital Partners LLP Invests $2.31 Million in Axsome Therapeutics, Inc. $AXSM

GSA Capital Partners LLP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the second quarter, according to its most recent filing with the SEC. The fund purchased 9,419 shares of the company’s stock, valued at approximately $2,305,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new stake in Axsome Therapeutics in the fourth quarter worth $31,000. Ameriflex Group Inc. acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $37,000. Hollencrest Capital Management increased its stake in shares of Axsome Therapeutics by 400.0% during the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after acquiring an additional 160 shares during the period. Farther Finance Advisors LLC raised its holdings in Axsome Therapeutics by 602.6% during the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after purchasing an additional 235 shares in the last quarter. Finally, Advisory Services Network LLC bought a new stake in Axsome Therapeutics during the third quarter worth approximately $40,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Down 0.0%

AXSM stock opened at $213.67 on Friday. Axsome Therapeutics, Inc. has a 52-week low of $108.04 and a 52-week high of $260.19. The company’s 50 day simple moving average is $235.53 and its 200-day simple moving average is $205.05. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.32. The firm has a market capitalization of $11.19 billion, a P/E ratio of -56.98 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The firm had revenue of $218.38 million during the quarter, compared to analyst estimates of $221.11 million. As a group, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.7 EPS for the current year.

Insider Buying and Selling

In related news, Director Mark Coleman sold 643 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total value of $160,107.00. Following the completion of the sale, the director directly owned 30,389 shares of the company’s stock, valued at approximately $7,566,861. This represents a 2.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Susan Mahony sold 300 shares of Axsome Therapeutics stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total value of $71,163.00. Following the transaction, the director directly owned 1,129 shares in the company, valued at approximately $267,810.09. This trade represents a 20.99% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 200,766 shares of company stock valued at $46,685,646. 20.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

AXSM has been the subject of several research reports. Royal Bank Of Canada reduced their price objective on shares of Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a research report on Tuesday. BMO Capital Markets began coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $258.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. HC Wainwright restated a “buy” rating and issued a $290.00 target price on shares of Axsome Therapeutics in a report on Wednesday, July 15th. Finally, Zacks Research lowered Axsome Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, July 20th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $267.60.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.